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Abstract
A library of dendrimers was synthesized and optimized for targeted small interfering RNA 
(siRNA) delivery to different cell subpopulations within the liver. Using a combinatorial 
approach, a library of these nanoparticle-forming materials was produced wherein the free amines 
on multigenerational poly(amido amine) and poly(propylenimine) dendrimers were substituted 
with alkyl chains of increasing length, and evaluated for their ability to deliver siRNA to liver cell 
subpopulations. Interestingly, two lead delivery materials could be formulated in a manner to alter 
their tissue tropism within the liver – with formulations from the same material capable of 
preferentially delivering siRNA to (i) endothelial cells, (ii) endothelial cells and hepatocytes, or 
(iii) endothelial cells, hepatocytes and tumor cells in vivo. The ability to broaden or narrow the 
cellular destination of siRNA within the liver may provide a useful tool to address a range of liver 
diseases.
Graphical Abstract
Dendrimer derivatives optimized for in vivo siRNA delivery to liver endothelial cells, 
hepatocellular carcinoma cells and/or hepatocytes are prepared using a combinatorial approach. 
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The free amines on multigenerational poly(amido amine) and poly(propylenimine) dendrimers are 
substituted with alkyl chains of increasing length. Through formulation changes, these materials 
have the ability to broaden or narrow their targeted cellular subpopulation within the liver.
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RNA interference (RNAi) is the process whereby a small interfering RNA (siRNA) induces 
the degradation of complimentary mRNA gene transcripts, thus silencing genes.[1] A key 
need to the broad application of RNAi is the development of safe and effective delivery 
systems capable of silencing genes in specific cells within the body. This type of selectivity 
has the potential to focus therapy, and thereby decrease side effects. Nanoformulation of 
siRNA is one approach towards this end, and to date the most advanced strategies are 
hepatocyte-specific, having both selectivity and potency in non-human primates and clinical 
trials.[2] There is an increasing collection of reports of siRNA delivery to tissues other than 
hepatocytes including tumors,[3] immune cells[4] and the endothelium.[5] However, delivery 
to these other tissues is often non-specific, with siRNA functionally delivered to more than 
just the target tissue. Here we report on the development of formulations based on 
dendrimeric materials where the targeting is tuned through modifying formulation 
parameters. Particular focus was placed on developing new delivery materials capable of 
silencing genes in different liver cell subpopulations, with special emphasis placed on blood 
vessel endothelial cells.
The chemically-modified dendrimer materials were synthesized using Michael addition 
chemistry by combining poly(amido amine) or poly(propylenimine) dendrimers of 
increasing generations with alkyl epoxides of various carbon chain lengths, as illustrated in 
Scheme 1. The resulting branched, amine-rich ionizable dendrimer cores that facilitate 
efficient complexation with negatively charged siRNA under acidic formulation conditions. 
Modification of the dendrimers with alkyl chains affords lipid-like properties, promoting 
particle formation through hydrophobic aggregation in aqueous conditions. While 
polycationic polymers for siRNA delivery materials are generally polydisperse and often 
possess random branching,[6] these modified dendrimers can be molecularly defined, with 
monodisperse dendrimer cores and defined branching. Poly(amido amine) and 
poly(propylenimine) dendrimers have been previously investigated for their utility in siRNA 
delivery.[7] However, the alkyl modification reported here allow for the formation of lipid-
like nanoparticles with additional lipid components (excipients). These excipients can be 
used to tune the properties and activity of the resulting dendrimer.
Products were purified using flash chromatography to remove any unreacted starting 
materials. The products contained a mixture of different substitutions as well as chiral 
isomers when examined using thin layer chromatography (0.4 < Rf < 0.8 for an 87.5:11:1.5 
CH2Cl2:MeOH:NH4OHaq solvent system). These materials were screened for siRNA 
delivery using a HeLa cell line that stably expressed both firefly and Renilla luciferase.[8] 
Modified dendrimer nanoparticles were complexed with siRNA against firefly luciferase at a 
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5:1 ratio of modified dendrimer to siRNA, by mass. The Renilla luciferase was used as an 
internal viability control. For this initial high-throughput screen, modified dendrimers were 
only formulated with 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (C14PEG2000), at a 4:1 molar ratio of modified 
dendrimer to C14PEG2000. As shown in Figure 1a, all evaluated dendrimers demonstrated 
significant reduction in the expression of firefly luciferase when compared to PBS-treated 
controls, with differential activity dependent on the specific chemistry used. Nanoparticle 
uptake into HeLa cells was verified using confocal microscopy for dendrimers formulated 
with Cy5.5-labelled siRNA (Figure 1b & 1c).
Modified dendrimers were validated in vivo for the simultaneous delivery of siRNA to both 
liver endothelial cells and hepatocytes. Using the same formulation conditions as were used 
in the initial in vitro screen, modified dendrimers were co-formulated with two siRNAs 
against tie2 and Factor VII (FVII). Tie2 was selected as a target for silencing because it is an 
endothelial cell-specific target gene.[9] FVII, meanwhile, has been previously established as 
a robust target for hepatocyte-specific delivery.[8, 10] After co-formulation, modified 
dendrimer nanoparticles were injected into the tail veins of healthy 8 week old female 
C57BL/6 mice. After 2 days, mice were euthanized, and tie2 gene and FVII protein levels 
were quantified (Figure 2a).
Based on their ability to simultaneously silence genes in both liver endothelial cells and 
hepatocytes, PG1.C12 and PG1.C15 were selected as the top performing materials. These 
two materials had an identical core consisting of the first generation poly(amido amine) 
dendrimer (i.e. PG1), but varied in the length of the substituted alkyl chains (i.e. C12 vs. C15; 
refer to Scheme S1, and Figures S1 & S2 in Supporting Information). PG1.C15 
nanoparticles were larger in diameter and were more resistant to degradation in blood serum 
(Figures S3 & S4, respectively, in Supporting Information). The apparent nanoparticle pKa 
values of the two lead materials were ≥ 5.5 (Figure S5 & Table S1 in Supporting 
Information). Previous studies have shown that apparent nanoparticle pKa values ≥ 5.5 often 
correlate to hepatocyte delivery,[11] which corresponds to the findings reported here. The 
lead materials’ affinity for the liver was further confirmed and visualized with 
biodistribution studies (Figure S6 in Supporting Information). Tie2 knockdown was also 
quantified in the endothelium of other organs, but the effect was most potent in the liver 
(Figure S7 in Supporting Information). Moreover, no significant silencing was observed in 
immune cell populations when these materials were complexed with siRNA against the pan-
leukocyte marker CD45 (Figure S8 in Supporting Information).
To establish the relative potency of siRNA delivery to endothelial cells and hepatocytes, a 
dose response was generated with both PG1.C12 and PG1.C15 nanoparticles. In these 
experiments, particles were co-formulated with FVII and tie2 siRNA (Figure 2b). As was 
done in the initial in vivo screens, these co-formulated particles used C14PEG2000 as the 
only excipient. As shown in Figure 2b, significant knockdown of tie2 in the liver 
endothelium was achieved with an siRNA dose of 1 mg kg−1, while a similar degree of FVII 
knockdown was observed using only an siRNA dose of 0.125 mg kg−1. Because these 
nanoparticles were formulated to contain both siRNAs, the difference in siRNA efficiency 
for each gene indicates that both nanoparticle formulations had a higher silencing potency in 
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hepatocytes, and a reduced potency in liver endothelial cells. Thus, in order to compensate 
for reduced potency in the liver endothelium, a higher loading of the desired endothelial-
specific siRNA would be required for a strategy designed to silence both endothelial and 
hepatic gene expression to the same extent.
After establishing which siRNA doses were necessary for gene knockdown in endothelial 
cells and hepatocytes, we next sought to boost nanoparticle performance through changes in 
formulation. Cholesterol is an important component in the lipid envelope of viruses[12] and 
has been used in many potent nanoparticle formulations.[2a–c, 2e] Thus, we sought to 
evaluate the effects of altering the amount of cholesterol in these formulations. For these 
studies, the total dose of siRNA as well as the ratio of tie2:FVII siRNA were kept constant 
so only the cholesterol composition was varied. Moreover, the siRNA dose used in these 
studies was informed by previous experiments (Figure 2b) in order to control for differences 
in siRNA efficiency between the two cell types. Figure 2c shows that PG1.C15 
nanoparticles formulated at a 90:2:8 mass ratio of modified 
dendrimer:cholesterol:C14PEG2000 targeted both hepatocytes and liver endothelial cells, as 
was seen previously in cholesterol-free formulations. However, when the amount of 
cholesterol and C14PEG2000 was reduced to achieve a 98:1:1 formulation ratio, the same 
nanomaterial demonstrated increased potency and specificity in liver endothelial cells and 
significantly reduced potency in hepatocytes. Similarly, endothelial-specific targeting with 
reduced hepatocyte potency was seen for the PG1.C12 when the formulation was changed 
from 89:2:9 to 97:1:2, though the efficiency of PG1.C12 as a delivery materials is not as 
potent as PG1.C15 (Figure 2d). Negative controls for nanoparticles formulated with a non-
functional scrambled siRNA showed no knockdown for any of the tested formulations in 
either cell type (Figure S9 in Supporting Information). Interestingly, nanoparticles in the 
endothelial-specific formulations were larger in diameter than those that did not demonstrate 
similar selectivity (Figure 2e & 2f). While all of the modified dendrimer nanoparticles 
evaluated here resulted in no dramatic increase in blood plasma cytokine levels at 48 hours 
following administration, formulations with higher cholesterol content resulted in fewer 
fluctuations in cytokine levels relative to baseline (Figure S10 in Supporting Information).
Therefore, though the PG1.C12 and PG1.C15 modified dendrimers both can enable 
simultaneous delivery of siRNAs to multiple liver cell types, they can be formulated such 
that the potency of delivery to hepatocytes is reduced while delivery to endothelial cells is 
maintained or enhanced. This was achieved by co-formulating with cholesterol as an 
additional excipient in the nanoparticles, while maintaining a constant 5:1 mass ratio for 
modified dendrimer:siRNA. Depending on the ratio of cholesterol and C14PEG2000 in the 
formulations, the targeted liver cell subpopulation can be varied.
After investigating gene silencing in the endothelial cells and hepatocytes of normal, non-
diseased livers, silencing was examined in liver tumor cells. Liver tumors contain a 
heterogeneous mixture of cells, including cancerous cells, normal hepatic cell types, and 
endothelial cells.[13] Using the minimal excipient formulation (4:1 modified 
dendrimer:C14PEG2000 molar ratio and 5:1 modified dendrimer:siRNA mass ratio), 
PG1.C12 and PG1.C15 were evaluated for delivery to hepatocellular carcinoma cells in 
Met-driven tumors.[14] Unlike normal adult hepatocytes, tumor cells in these hepatocellular 
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carcinomas specifically express and secrete Alpha-fetoprotein (AFP) into the blood.[15] 
Thus, as a model system for delivery to hepatocellular carcinoma, modified dendrimer 
nanoparticles formulated with siRNA for AFP were evaluated in this Met-driven AFP-
expressing tumor model. As shown in Figure 3, PG1.C12 and PG1.C15 showed a 51% and 
92% knockdown (respectively) of AFP at a 1 mg kg−1 dose. Thus, in the context of these 
two lead materials, changing the length of the substituted alkyl chains adds an additional 
formulation guideline for delivery to various liver cell types. At the siRNA doses and ratios 
reported here, cholesterol-free formulations of PG1.C12 preferentially silenced genes in 
endothelial cells and healthy hepatocytes, and reduced silencing in the tumors. In contrast, 
cholesterol-free formulations of PG1.C15 increased silencing in tumor cells but had similar 
efficacy in endothelial cells and healthy hepatocytes at the same dose (Figures 2b & 3b).
This work describes the potential to bias silencing to multiple tissues, including the liver 
endothelium, hepatocellular carcinoma cells, and hepatocytes, in a controlled and tunable 
way, via formulation. With the two lead modified dendrimers presented here, preferential 
silencing can be influenced by varying the excipient ratio and changing the length of 
substituted alkyl chains. Nanoparticle formulations with higher endothelial cell selectivity 
were larger in diameter (Figures 2e & 2f). These larger sizes may have played a role in 
selective delivery by affecting transport of nanoparticles through the fenestrated 
endothelium of the liver, thus reducing hepatocyte access and uptake.[16] Furthermore, the 
changes in excipient content may have altered blood serum protein adsorption to the 
nanoparticles, which may have in turn altered liver cell subpopulation uptake. Lipid-based 
nanoparticles are known to exchange components with the serum and adsorb proteins.[17] 
Apolipoprotein E is a serum protein that can adsorb to nanoparticles and enhance uptake 
into hepatocytes.[18] Thus, one hypothesis is that the endothelial-specific formulations 
reduce their affinity for apolipoprotein E, which may subsequently diminish hepatocyte 
uptake and gene knockdown.
In regards to hepatocellular carcinoma gene silencing efficiency, a number of factors, 
including particle size, charge, stability and retention time, may have contributed to the 
observed difference in potency. While these modified dendrimers contained the same core, 
the lengths of their substituted alkyl chains differed; PG1.C12 had C12 alkyl chains while 
PG1.C15 had longer C15 chains. Once formulated, PG1.C15 nanoparticles were larger and 
more stable in blood serum (Figures S3 & S4 in Supporting Information). The increased 
serum stability may have increased the circulation time of the intact nanoparticles, allowing 
them more opportunity to reach their target. Moreover, the larger size of the PG1.C15 
nanoparticles may have improved their retention time within the tumor.[19] Additionally, as 
indicated by zeta potential data (Table S1 in Supporting Information), PG1.C15 
nanoparticles were more prone to aggregation. Perhaps, after nanoparticle entry into the 
tumor, their effective size increased through accretion, which possibly enhanced 
nanoparticle retention even further.
The ability to bias delivery to liver endothelial cells may prove useful when the target genes 
are expressed in both hepatocytes and endothelial cells, but therapy requires only silencing 
in the endothelium. A potential example of this could include the treatment of inflamed liver 
endothelium, which often occurs in liver disease. In contrast, it is possible that delivery to 
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both hepatocytes and endothelium could be useful when diseases affect both tissues, such as 
in the case of ischemia/reperfusion injuries caused by liver surgery and transplantation.[20]
Alkyl substitution of regularly branched dendrimer structures to produce amphiphiles rich 
with primary, secondary and tertiary amines is a facile strategy to prepare nanoparticles that 
can condense siRNA for targeted delivery. Moreover, the use of molecularly defined, 
regularly-branched, ionizable dendrimers as the core structure for these materials is 
advantageous with respect to clinical translation. Future formulations of these materials 
could be considered for the delivery of other therapeutic nucleic acids, such as mRNA, 
microRNA, and DNA.
Experimental Section
Refer to the Supporting Information section online via the link at the end of the document.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) A representative subset of the full in vitro screen of modified dendrimers showing HeLa 
luciferase luminescence after knockdown of firefly luciferase at a 25 nM siRNA dose. 
Renilla luminescence was used as an internal control to both gauge off-target effects and 
modified dendrimer-induced toxicity. Dendrimers (including a Lipofectamine positive 
control) are listed on the x-axis and luciferase luminescence is shown on the y-axis. For 
nomenclature, P = poly(amido amine), D = diaminobutane amine poly(propylenimine) 
tetramine, G# = generation number and C# = number of carbons in the alkyl chain. N=3 and 
error bars are ± S.D. (b, c) Confocal images of PG1.C12 (b) and PG1.C15 (c) nanoparticle 
delivering Cy5.5-labelled siRNA into HeLa cells at a 50 nM dose. Nanoparticles are red, 
cell membrane green and nuclei blue. Scale bar = 10 μm.
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(a) An example of an in vivo multigenerational modified dendrimer screen using 
C14PEG2000 as the only formulation excipient. Modified dendrimer nanoparticles were co-
formulated with tie2 and FVII siRNAs. The total siRNA dose was 3.7 mg kg−1; 1.2 mg kg−1 
of FVII siRNA and 2.5 mg kg−1 tie2 siRNA. The co-formulated particles simultaneously 
caused knockdown of both genes in the liver 2 days after tail vein injection. (b) In vivo 
performance of PG1.C12 and PG1.C15 modified dendrimer nanoparticles co-formulated tie2 
and FVII siRNAs two days after tail vein injection. C14PEG2000 was the only excipient. For 
the higher dose, a total siRNA dose was 1.125 mg kg−1 (1 mg kg−1 tie2 siRNA and 0.125 
mg kg−1 FVII siRNA) was used. The lower dose had a total siRNA dose of 0.51 mg kg−1 
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(0.5 mg kg−1 tie2 siRNA and 0.01 mg kg−1 FVII siRNA). * = p < 0.04 (t-test) for 
comparison between doses. (c, d) Optimized nanoparticles containing C14PEG2000 and 
cholesterol as excipients were co-formulated with FVII and tie2 siRNAs. The combined 
siRNA dose was 2.6 mg kg−1; 2.5 mg kg−1 tie2 siRNA and 0.1 mg kg−1 FVII siRNA. 
Expression was measured 2 days after tail vein injections. N = 3 and * = p < 0.02 for 
comparisons between formulations. (c) Both formulations of PG1.C15 resulted in tie2 
knockdown in liver endothelial cells. However, the low excipient 98:1:1 formulation 
stopped delivery to hepatocytes. (d) Both PG1.C12 formulations caused knockdown in the 
liver endothelium, while the low excipient 97:1:2 formulation prevented hepatocyte 
delivery. (e, f) The reduced excipient formulations that resulted in hepatocyte exclusion also 
increased the mean size of the nanoparticles and reduced their polydispersity. All error bars 
are ± S.D.
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(a) Serum protein Western blot showing in vivo alpha-fetoprotein (AFP) knockdown in 
hepatocellular carcinoma cells using PG1.C12 and PG1.C15 modified dendrimers. 
Nanoparticles were formulated at a 4:1 modified dendrimer:C14PEG2000 molar ratio and a 1 
mg kg−1 siRNA dose was used. (b) Densitometry analysis of the blot showed that both 
modified dendrimers caused a significant decrease in the amount of AFP in the blood. 
PG1.C15 was the more potent of the two formulations. N = 3, error bars are 1 S.D. and 
connecting lines indicate a significant difference (p < 0.05, t-test).
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Synthesis of chemically-modified dendrimer materials. Epoxide-terminated alkyl chains 
ranging in size from C10 to C16 were reacted with the free amines on poly(amido amine) or 
poly(propylenimine) dendrimers of increasing generation size. In this example, PG0, or 
generation 0 poly(amido amine), is reacted with an alkyl epoxide.
Khan et al. Page 12
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2016 March 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
